China's expanded 2012 essential drugs list could open market to foreign suppliers
This article was originally published in Scrip
In 2012, China's key healthcare priorities will include an expansion of the national essential drugs list and the improvement of the primary medical care system in rural areas, according to a new policy plan released recently by the ministry of health (MoH).
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.